A Study to Assess the Efficacy, Safety, and Pharmacokinetics of ABP-671 in Patients With Gout or Hyperuricemia
Status:
Recruiting
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled, dose-ranging
study to evaluate the efficacy, safety, and pharmacokinetics study of 6 different dose
regimens of ABP-671 compared with placebo. The study will consist of three sequential groups
with escalating total daily ABP-671 doses. Each group is further divided into two dose
cohorts with either QD or BID dosing. Each dose group will have 3 stages following screening:
Run-in, Dose Evaluation, and Follow-up.
Phase:
Phase 2
Details
Lead Sponsor:
Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.